When combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 after autologous HSCT, a statistically significant improvement in progression-free survival was observed in neuroblastoma [20]. This evidence concerns the gene IL2 and neuroblastoma.